|
⚲
|
| Keyboard |
| Versant Vantage I GP LP
✚
|
|
|---|---|
| CIK # | 0001777651 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001777651] | |
| 4 | [0001777651] |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Monte Rosa Therapeutics Inc GLUE
Common Stock
|
2024-10-29 | Sell | 52,305 | $9.08 | 474,929 |
|
Monte Rosa Therapeutics Inc GLUE
Common Stock
|
2024-10-29 | Sell | 15,600 | $9.41 | 146,796 |
|
Monte Rosa Therapeutics Inc GLUE
Common Stock
|
2024-10-28 | Sell | 89,990 | $9.66 | 869,303 |
|
Monte Rosa Therapeutics Inc GLUE
Common Stock
|
2024-10-28 | Other | 17,595 | $0.00 | |
|
Monte Rosa Therapeutics Inc GLUE
Common Stock
|
2024-10-28 | Other | 20,397 | $0.00 | |
|
Monte Rosa Therapeutics Inc GLUE
Common Stock
|
2024-10-28 | Other | 20,397 | $0.00 | |
|
Monte Rosa Therapeutics Inc GLUE
Common Stock
|
2024-10-28 | Other | 1,019,867 | $0.00 | |
|
Monte Rosa Therapeutics Inc GLUE
Common Stock
|
2024-10-28 | Other | 366,590 | $0.00 | |
|
Monte Rosa Therapeutics Inc GLUE
Common Stock
|
2024-10-28 | Other | 5,454 | $0.00 | |
|
Monte Rosa Therapeutics Inc GLUE
Common Stock
|
2024-10-28 | Other | 5,454 | $0.00 | |
|
Monte Rosa Therapeutics Inc GLUE
Common Stock
|
2024-10-28 | Other | 5,499 | $0.00 | |
|
Monte Rosa Therapeutics Inc GLUE
Common Stock
|
2024-10-28 | Other | 5,499 | $0.00 | |
|
Monte Rosa Therapeutics Inc GLUE
Common Stock
|
2024-10-28 | Other | 17,595 | $0.00 | |
|
Monte Rosa Therapeutics Inc GLUE
Common Stock
|
2024-09-20 | Sell | 1,132,566 | $6.53 | 7,395,656 |
|
Monte Rosa Therapeutics Inc GLUE
Common Stock
|
2024-09-13 | Sell | 9,269 | $6.16 | 57,097 |
|
Monte Rosa Therapeutics Inc GLUE
Common Stock
|
2024-09-12 | Sell | 16,047 | $6.00 | 96,282 |
|
Monte Rosa Therapeutics Inc GLUE
Common Stock
|
2024-09-11 | Sell | 541,897 | $6.00 | 3,251,382 |
|
Contineum Therapeutics Inc CTNM
Series C Preferred Stock · derivative
|
2024-04-09 | Conversion | 275,769 | ||
|
Contineum Therapeutics Inc CTNM
Series C Preferred Stock · derivative
|
2024-04-09 | Conversion | 689 | ||
|
Contineum Therapeutics Inc CTNM
Series A-1 Preferred Stock · derivative
|
2024-04-09 | Conversion | 1,423,119 | ||
| showing 20 of 200 most recent transactions | |||||